Drug intelligence / Profile preview

mAb57-24

Development stage: Discontinued
Lead developer: LeafBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mAb57-24 is a monoclonal antibody developed by Mapp Biopharmaceutical and its commercial arm, LeafBio, for the treatment of Ebola virus disease caused by the Zaire ebolavirus. Administered via intravenous infusion, the antibody is designed to neutralize the virus by targeting the Ebola virus glycoprotein, thereby preventing viral entry into host cells. According to company pipeline records, the development of mAb57-24 for this indication has been discontinued.

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on mAb57-24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb57-24.

Explore the full profile